

# Anti-IL-17 $\alpha$ (Secukinumab), Human IgG1 Antibody

rev 02/21

---

**CATALOG NO.:** A2154-100 (100  $\mu$ g)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a human IgG1 monoclonal antibody that targets IL-17 $\alpha$  and prevents its association with the receptor IL-17R. This results in decreased release of proinflammatory cytokines and chemokines and downregulation of inflammation. IL-17 represents a family of cytokines (IL-17 A-F) that is released by T-helper-17 (Th17) cells, mast cells, neutrophils, and dendritic cells and promotes inflammation. Studies show that IL-17 is associated with multiple autoimmune diseases such as rheumatoid arthritis, spondyloarthritis, psoriasis, Crohn's disease, and multiple sclerosis. The original monoclonal antibody received approval from the FDA to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

**ALTERNATE NAMES:** IL17, CTLA8, IL-17, CTLA-8, IL17A

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** Lot specific

**HOST/ISOTYPE:** Recombinant / IgG1, kappa

**IMMUNOGEN:** Human IL-17 $\alpha$

**MOLECULAR WEIGHT:** 147.94 kDa

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C. Avoid freeze/thaw cycles

**APPLICATIONS AND USAGE:** *In vitro* studies

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IL-12 $\beta$  (Ustekinumab), Human IgG1 Antibody (A2137)  
 Anti-IL-1 $\beta$  (Canakinumab), Human IgG1 Antibody (A2144)  
 Anti-TNF- $\alpha$  (Golimumab), Human IgG1 Antibody (A2141)  
 Anti-IL-23 $\alpha$  (Guselkumab), Human IgG1 Antibody (A2147)  
 Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)

**FOR RESEARCH USE ONLY! Not to be used on humans.**